Theriva Biologics, Inc., formerly Synthetic Biologics, Inc., is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of unmet need. The Company is engaged in the development of oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient's immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)